Effects of Extended‐Release Methylphenidate on Dopamine and Norepinephrine Transporters in Adults With Attention‐Deficit/Hyperactivity Disorder: A Longitudinal Dual‐Tracer PET Study
Psychiatry and Clinical Neurosciences · 2026-01 · 80 (1) · 48-54
DOI: 10.1111/pcn.13911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatry and Clinical Neurosciences, online erschienen am 23.10.2025. Verfasst von Masaki Oya und 21 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Methylphenidate, Norepinephrine Plasma Membrane Transport Proteins, Dopamine Plasma Membrane Transport Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Science and Technology Agency, Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Aim
Attention‐deficit/hyperactivity disorder (ADHD) is associated with dysregulation of dopamine and norepinephrine neurotransmission. Extended‐release methylphenidate (MPH), a first‐line treatment for ADHD, modulates these systems. However, its specific effects on the dopamine transporter (DAT) and norepinephrine transporter (NET) are inadequately characterized. This study evaluated the effects of MPH on DAT and NET binding in adults with ADHD and examined the relationship between transporter binding and cognitive improvement.
Methods
This longitudinal dual‐tracer positron emission tomography (PET) study used [ 18 F]‐FEPE2I for DAT imaging and (S,S)‐[ 18 F]‐ FMeNER‐D2 for NET imaging. PET imaging and cognitive assessments were conducted on 21 adults with ADHD before MPH treatment, and 12 of these participants were reevaluated after achieving treatment stabilization.
Results
MPH treatment significantly decreased DAT binding in the caudate and putamen and NET binding in the thalamus and pons. Improvements in attention and multitasking abilities were observed. Baseline NET binding in the pons was higher in individuals with ADHD than in controls, and higher baseline DAT binding in the putamen predicted improvement in sustained attention. However, changes in DAT and NET binding did not correlate with cognitive improvement. Blood concentration analysis revealed that even at MPH blood levels that resulted in high DAT occupancy in the striatum, NET occupancy in the thalamus remained moderate.
Conclusions
MPH simultaneously reduced DAT and NET binding in ADHD, enhanced dopamine and norepinephrine transmission, and improved cognitive function. The differential occupancy of DAT and NET suggests distinct contributions to the therapeutic effects of MPH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
- Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- Department of Psychiatry, Nara Medical University, Nara, Japan.
- Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
ORCID-Profile: Masaki Oya, Manabu Kubota, Masanori Ichihashi, Masaaki Shimizu
Förderung
- Japan Science and Technology Agency
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Oya, M., Matsuoka, K., Kubota, M., Kitamura, S., Kataoka, Y., Kokubo, N., Takahata, K., Seki, C., Endo, H., Tagai, K., Takado, Y., Hirata, K., Ichihashi, M., Kurose, S., Kato, N., Sugihara, G., Shimizu, M., Takagi, S., Ito, W., …, & Takahashi, H. (2026). Effects of Extended‐Release Methylphenidate on Dopamine and Norepinephrine Transporters in Adults With Attention‐Deficit/Hyperactivity Disorder: A Longitudinal Dual‐Tracer PET Study. Psychiatry and Clinical Neurosciences, 80(1), 48-54. https://doi.org/10.1111/pcn.13911
Vancouver
Oya M, Matsuoka K, Kubota M, Kitamura S, Kataoka Y, Kokubo N, et al. Effects of Extended‐Release Methylphenidate on Dopamine and Norepinephrine Transporters in Adults With Attention‐Deficit/Hyperactivity Disorder: A Longitudinal Dual‐Tracer PET Study. Psychiatry and Clinical Neurosciences. 2026;80(1):48-54. doi:10.1111/pcn.13911
BibTeX
@article{Oya2026,
author = {Oya, Masaki and Matsuoka, Kiwamu and Kubota, Manabu and Kitamura, Soichiro and Kataoka, Yuko and Kokubo, Naomi and Takahata, Keisuke and Seki, Chie and Endo, Hironobu and Tagai, Kenji and Takado, Yuhei and Hirata, Kosei and Ichihashi, Masanori and Kurose, Shin and Kato, Nobumasa and Sugihara, Genichi and Shimizu, Masaaki and Takagi, Shunsuke and Ito, Wakako and Nakamura, Motoaki and Higuchi, Makoto and Takahashi, Hidehiko},
title = {Effects of Extended‐Release Methylphenidate on Dopamine and Norepinephrine Transporters in Adults With Attention‐Deficit/Hyperactivity Disorder: A Longitudinal Dual‐Tracer PET Study},
journal = {Psychiatry and Clinical Neurosciences},
year = {2026},
volume = {80},
number = {1},
pages = {48--54},
doi = {10.1111/pcn.13911}
}
EUVIMED